The global cancer biomarkers market is estimated to grow from USD 25.9 billion in the current year to USD 37.8 billion by 2035, at a CAGR of 4.3% during the forecast period, till 2035.
To address this critical unmet need, the healthcare industry has increasingly adopted cancer biomarkers as a cornerstone of modern oncology diagnostics. The demand for such biomarkers is primarily driven by the molecular heterogeneity of cancer, wherein patients diagnosed with the same cancer type and disease stage often exhibit distinct molecular and genetic profiles, resulting in variable responses to recombinant drugs and biologic therapies. In response, pharmaceutical developers and healthcare providers have progressively shifted toward precision oncology approaches. Through the identification of disease-specific molecular signatures, clinicians are now able to customize treatment strategies for individual patients, moving beyond the conventional “one-size-fits-all” therapeutic model.
Although single-analyte biomarkers, such as PD-L1, BRAF, and EGFR, continue to play a foundational role in oncology diagnostics, their predictive capabilities are often limited in the context of complex genomic landscapes and long-term treatment efficacy. As a result, advancements in high-throughput technologies, particularly next-generation sequencing (NGS), have facilitated the development and validation of more comprehensive biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI). These advanced biomarkers offer deeper understanding of genomic instability and tumor biology, enabling more precise patient stratification and treatment selection.
The expanding pipeline of clinically validated biomarkers remains a key driver of market growth. Supported by substantial investments from leading pharmaceutical and biotechnology companies in multi-omics and precision medicine initiatives, the cancer biomarkers market is positioned for significant expansion, with data-driven diagnostic integration expected to redefine the future standard of oncology care.
These innovations enable clinicians to identify patient-specific molecular signatures, improving therapeutic selection, reducing treatment-related toxicities, and enhancing survival outcomes across multiple cancer indications. Further strengthening market expansion, leading pharmaceutical and biotechnology companies, including Roche and Novartis, are actively investing in biomarker-driven clinical trials and companion diagnostic development to support targeted immuno-oncology therapies. In parallel, increasing regulatory approvals for companion diagnostics and expanded indications for immunotherapies are reinforcing the market’s upward trajectory, positioning cancer biomarkers as a critical component of next-generation oncology care.
The market also faces challenges associated with limited large-scale clinical validation and the absence of standardized data frameworks, as many emerging biomarkers are yet to demonstrate consistent clinical utility across diverse patient populations. Variability in assay methodologies, reporting standards, and data formats across laboratories further complicates data integration, comparative analyses, and routine implementation in oncology practice. Moreover, the evolving and region-specific regulatory landscape for biomarker-based diagnostics and companion tests, overseen by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, continues to create uncertainty for market participants. It increases compliance requirements, prolongs approval timelines, and raises overall commercialization costs.
In contrast, the EGFR biomarker testing segment is anticipated to witness comparatively faster growth during the forecast period. This growth is primarily driven by the increasing global prevalence of lung cancer, along with the rising adoption of precision oncology and targeted treatment approaches. In particular, the growing clinical utilization of EGFR inhibitors, such as Osimertinib, has significantly increased the demand for EGFR mutation testing to support patient stratification and treatment selection in non-small cell lung cancer (NSCLC).
Looking ahead, the melanoma biomarker testing segment is anticipated to grow at a relatively faster pace, with a projected CAGR of 4.5% during the forecast period. This growth is primarily driven by the increasing global incidence of melanoma, continued advancements in targeted therapies, and the growing adoption of precision diagnostic approaches. In particular, the clinical uptake of BRAF and MEK inhibitors, alongside rising utilization of BRAF mutation testing and liquid biopsy-based biomarker assays, is expected to significantly contribute to segment expansion.
Cancer Biomarkers Market: Growth and Trends
Over the past two decades, researchers and biopharmaceutical companies have introduced several advanced and highly effective cancer treatment modalities, including targeted therapies, immunotherapies, and therapeutic cancer vaccines. Despite these advancements, oncology research continues to encounter significant challenges, including systemic treatment-related toxicities, high clinical trial attrition rates, and various pharmacological and therapy-specific limitations. These persistent challenges underscore the growing need for more precise and reliable diagnostic frameworks capable of improving patient outcomes while minimizing the economic impact associated with therapeutic failure.To address this critical unmet need, the healthcare industry has increasingly adopted cancer biomarkers as a cornerstone of modern oncology diagnostics. The demand for such biomarkers is primarily driven by the molecular heterogeneity of cancer, wherein patients diagnosed with the same cancer type and disease stage often exhibit distinct molecular and genetic profiles, resulting in variable responses to recombinant drugs and biologic therapies. In response, pharmaceutical developers and healthcare providers have progressively shifted toward precision oncology approaches. Through the identification of disease-specific molecular signatures, clinicians are now able to customize treatment strategies for individual patients, moving beyond the conventional “one-size-fits-all” therapeutic model.
Although single-analyte biomarkers, such as PD-L1, BRAF, and EGFR, continue to play a foundational role in oncology diagnostics, their predictive capabilities are often limited in the context of complex genomic landscapes and long-term treatment efficacy. As a result, advancements in high-throughput technologies, particularly next-generation sequencing (NGS), have facilitated the development and validation of more comprehensive biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI). These advanced biomarkers offer deeper understanding of genomic instability and tumor biology, enabling more precise patient stratification and treatment selection.
The expanding pipeline of clinically validated biomarkers remains a key driver of market growth. Supported by substantial investments from leading pharmaceutical and biotechnology companies in multi-omics and precision medicine initiatives, the cancer biomarkers market is positioned for significant expansion, with data-driven diagnostic integration expected to redefine the future standard of oncology care.
Growth Drivers: Strategic Enablers of Market Expansion
The growing global burden of cancer, driven by aging populations, changing lifestyles, and increasing exposure to environmental risk factors, continues to accelerate the demand for advanced oncology diagnostics and targeted treatment approaches. In response to this rising disease prevalence, the healthcare industry is witnessing a significant shift toward precision oncology and personalized medicine, wherein treatment decisions are increasingly guided by individual tumor biology and molecular profiling. This transition has been strongly supported by rapid technological advancements in next-generation sequencing (NGS), liquid biopsy platforms, multi-omics technologies, bioinformatics, and artificial intelligence-enabled diagnostics, all of which have streamlined biomarker discovery, validation, and clinical implementation.These innovations enable clinicians to identify patient-specific molecular signatures, improving therapeutic selection, reducing treatment-related toxicities, and enhancing survival outcomes across multiple cancer indications. Further strengthening market expansion, leading pharmaceutical and biotechnology companies, including Roche and Novartis, are actively investing in biomarker-driven clinical trials and companion diagnostic development to support targeted immuno-oncology therapies. In parallel, increasing regulatory approvals for companion diagnostics and expanded indications for immunotherapies are reinforcing the market’s upward trajectory, positioning cancer biomarkers as a critical component of next-generation oncology care.
Market Challenges: Critical Barriers Impeding Progress
Despite the strong growth potential of the cancer biomarkers market, several operational, technical, and regulatory challenges continue to hinder widespread adoption and commercialization. One of the primary barriers is the high cost and extended timeline associated with biomarker research and development, as companies are required to invest substantial capital in discovery, validation, and regulatory approval processes before achieving clinical adoption. These financial and operational demands often restrict market participation, particularly among small and mid-sized biotechnology firms, while simultaneously delaying the introduction of innovative diagnostic solutions. In addition, technical limitations associated with sample collection, handling, and storage remain a significant concern. Improper processing can result in biomarker degradation, contamination, and inconsistent test results, ultimately compromising diagnostic accuracy and reducing clinical confidence in biomarker-based assays.The market also faces challenges associated with limited large-scale clinical validation and the absence of standardized data frameworks, as many emerging biomarkers are yet to demonstrate consistent clinical utility across diverse patient populations. Variability in assay methodologies, reporting standards, and data formats across laboratories further complicates data integration, comparative analyses, and routine implementation in oncology practice. Moreover, the evolving and region-specific regulatory landscape for biomarker-based diagnostics and companion tests, overseen by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, continues to create uncertainty for market participants. It increases compliance requirements, prolongs approval timelines, and raises overall commercialization costs.
Cancer Biomarkers Market: Key Insights
The report delves into the current state of the cancer biomarkers market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Advancements in biotechnology have led to the identification of several cancer biomarker testing solutions, which are presently being used for a variety of purposes, including diagnosis, clinical research and to facilitate therapy-related decision-making.
- Currently, more than 290 biomarker solutions are available in the market; around 85% of these solutions use next generation sequencing for the assessment of cancer biomarkers.
- Majority (68%) of the cancer biomarker testing solutions assist in the evaluation of indels; 85% of the testing solutions utilize next generation sequencing (NGS) for the assessment of cancer biomarkers.
- Several industry and non-industry players are conducting biomarker-stratified clinical trials to develop new targeted therapies; most of the patients were enrolled across multiple sites in China.
- The field of cancer biomarkers has seen a significant rise in research, with over 470 articles published by various researchers, underscoring the growing focus of several industry players and academic players in this domain.
- The cancer biomarkers market is expected to witness an annualized growth rate of 4.3% during the forecast period; notably, biomarker testing solutions for breast cancer are expected to capture the majority current market share.
- Driven by the growing adoption of personalized medicine in the US, the cancer biomarkers market is poised to grow at a higher CAGR during the forecast period.
- Given the rising prevalence of cancer, and the intensifying demand for precise, biomarker-driven diagnostics across clinical and research settings, the cancer biomarkers market is positioned for steady growth.
Cancer Biomarkers Market
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Biomarker
- HER2
- MET
- EGFR
- PD-L1
- NTRK
- ALK
- Other Biomarkers
By Type of Cancer
- Breast Cancer
- Colorectum Cancer
- Lung Cancer
- Prostate Cancer
- Thyroid Cancer
- Bladder Cancer
- Melanoma
- Non-Hodgkin Lymphoma
- Endometrial Cancer
- Kidney Cancer
- Leukemia
By Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
Cancer Biomarkers Market: Key Segments
Which Type of Biomarker Testing Accounts for the Largest Share in the Cancer Biomarkers Market?
In the current year, HER2 biomarker testing solutions are expected to account for the largest share (21.1%) of the cancer biomarkers market. This dominance is primarily attributed to the extensive clinical validation of HER2 testing in the diagnosis, prognosis, and therapeutic management of breast and gastric cancers. The segment’s strong market position is further reinforced by its direct association with several high-value targeted therapies, including Trastuzumab and Pertuzumab, which continue to drive sustained global demand for HER2-based companion diagnostics.In contrast, the EGFR biomarker testing segment is anticipated to witness comparatively faster growth during the forecast period. This growth is primarily driven by the increasing global prevalence of lung cancer, along with the rising adoption of precision oncology and targeted treatment approaches. In particular, the growing clinical utilization of EGFR inhibitors, such as Osimertinib, has significantly increased the demand for EGFR mutation testing to support patient stratification and treatment selection in non-small cell lung cancer (NSCLC).
Regional Analysis: Which Regions are Showing the Fastest Growth in the Cancer Biomarkers Testing Domain?
North America: Leading the Global Market
North America is expected to dominate the cancer biomarkers market, capturing 52.1% of the overall market revenue in the current year. The region’s leadership position can be attributed to the rising burden of cancer, well-established healthcare infrastructure, and the increasing adoption of personalized medicine and precision oncology frameworks. In addition, strong investments in biomarker research, widespread availability of advanced diagnostic technologies, and favorable regulatory and reimbursement environments continue to support market growth across the region.Which Type of Cancer Holds the Highest Share in the Market?
According to current market estimates, biomarker tests for breast cancer are projected to account for the largest share (25.1%) of the overall cancer biomarkers market revenue. This can be attributed to the high global prevalence of breast cancer as one of the leading causes of cancer-related mortality among women. As a result, there is significant demand for biomarker-driven diagnostics that support early detection, prognosis assessment, risk stratification, and personalized therapeutic interventions.Looking ahead, the melanoma biomarker testing segment is anticipated to grow at a relatively faster pace, with a projected CAGR of 4.5% during the forecast period. This growth is primarily driven by the increasing global incidence of melanoma, continued advancements in targeted therapies, and the growing adoption of precision diagnostic approaches. In particular, the clinical uptake of BRAF and MEK inhibitors, alongside rising utilization of BRAF mutation testing and liquid biopsy-based biomarker assays, is expected to significantly contribute to segment expansion.
Primary Research Overview
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:- Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships, Small Company, US
- Business Manager, Mid-sized Company, Germany
- Former Chief Scientific Officer, Large Company, US
Cancer Biomarkers Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cancer biomarkers market, focusing on key market segments, including [A] type of biomarker, [B] type of cancer and [C] geographical regions.
- Market Landscape: A comprehensive evaluation of testing solutions for novel cancer biomarkers, considering various parameters, such as [A] type of biomarker evaluated, [B] type of analytical technique used, [C] turnaround time, [D] type of sample supported, [E] type of nucleic acid tested, [F] type of cancer, [G] application area and [H] End-user. Additionally, it includes a detailed list of developers engaged in offering novel cancer biomarker testing solutions, along with analysis based on various parameters, such as [I] year of establishment, [J] company size (in terms of employee count) and [K] location of headquarters.
- Product Competitiveness Analysis: A comprehensive competitive analysis of novel cancer biomarker testing solutions, examining factors, such as product versatility and product competitiveness.
- Company Profiles: In-depth profiles of key industry players offering novel cancer biomarker testing solutions, focusing on [A] company overviews, [B] financial information, [C] cancer biomarker testing solutions portfolio, [D] recent developments and [E] an informed future outlook.
- Case Study: A general discussion on the innovative study designs involved in conducting biomarker-based clinical trial to evaluate drugs for oncological disorders. It includes details on the structure of each study design, highlighting their respective advantages and challenges.
- Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various novel cancer biomarkers based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] enrolled patient population, [E] type of sponsor / collaborator, [F] most active players (in terms of number of registered trials), [G] study design, [H] target therapeutic area and [I] key geographical regions.
- Publication Analysis: A detailed publication analysis of over 630 articles that have been published highlighting the key focus areas of ongoing research related to novel cancer biomarkers. It highlights the prevalent trends based on the [A] year of publication, [B] type of publication, [C] type of cancer, [D] copyright holders, [E] emerging focus areas, [F] most active publishers (in terms of number of publications) and [G] key journals (in terms of journal impact factor and number of articles published).
- Big Pharma Analysis: A comprehensive examination of various initiatives focused on cancer biomarkers undertaken by major pharmaceutical companies. This analysis includes heat map visualizations that illustrate the distribution of leading pharmaceutical firms, as well as spider web diagrams that compare their initiatives across multiple relevant parameters.
- Case Study 1 - Analysis Of Value Chain in the Companion Diagnostics Industry: A comprehensive value chain analysis that explores the various stages involved in the production of companion diagnostics. This includes a discussion on research and development (R&D), clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities and the cost distribution across each of the aforementioned stages.
- Case Study 2 - Future Growth Opportunities: A detailed discussion on the upcoming opportunities for cancer biomarker testing solution providers in this field that are likely to impact on the evolution of the market in the short to mid-term and mid to long-term.
- Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.
Key Questions Answered in this Report
- Which are the leading companies in the cancer biomarkers market?
- Which region dominates the cancer biomarkers market?
- What are the key trends observed in the cancer biomarkers market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by cancer biomarkers testing solution providers?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
Additional Benefits
- Complementary PPT Insights Pack
- Complementary Excel Data Packs for all Analytical Modules in the Report
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. PREFACE
2. RESEARCH METHODOLOGY
3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS
4. MACRO-ECONOMIC INDICATORS
5. EXECUTIVE SUMMARY
6. INTRODUCTION
7. MARKET LANDSCAPE
8. PRODUCT COMPETITIVENESS ANALYSIS
9. COMPANY PROFILES: CANCER BIOMARKERS TESTING SOLUTION PROVIDERS
10. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS
11. CLINICAL TRIAL ANALYSIS
12. PUBLICATION ANALYSIS
13. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS
14. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY
15. CASE STUDY: FUTURE GROWTH OPPORTUNITIES IN CANCER BIOMARKERS INDUSTRY
16. GLOBAL CANCER BIOMARKERS MARKET
17. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER
18. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER
19. CANCER BIOMARKERS MARKET, BY GEOGRAPHICAL REGIONS
21. EXECUTIVE INSIGHTS
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ARUP Laboratories
- Asper Biogene
- BioReference
- Caris Life Sciences
- CeGaT
- Foundation Medicine
- Genekor Medical
- Guardant Health
- IQVIA Laborateries
- Labcorp
- MedGenome
- NeoGenomics Laboratories
- Nonacus
- OncoDNA
- Quest Diagnostics
- Oxford Gene Technology
- Personal Genome Diagnostics
- PhenoPath
- Positive Biosciences
- Tempus
- Thermo Fisher Scientific
- YuceBio
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 336 |
| Published | June 2026 |
| Forecast Period | 2026 - 2035 |
| Estimated Market Value ( USD | $ 25.9 Billion |
| Forecasted Market Value ( USD | $ 37.8 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
